Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical Europe

EMEA Recommends Conditional European Marketing Authorization For Amgen's Vectibix

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Company requested a re-examination of its application for colorectal cancer after EMEA refused marketing approval in May.

You may also be interested in...



EU Pharma Denies Skirting Rules On Pediatric Cancer Drug Development

The European pharmaceutical industry has refuted claims that manufacturers are exploiting a loophole in EU legislation to avoid running non-lucrative trials for pediatric oncology drugs.

KRAS Mutation Effective Biomarker For Vectibix Success, Amgen Reports

Biotech adds to industry KRAS buzz with biomarker analysis from its “408” study of the anti-EGFR comparing effectiveness against wild-type and mutated tumors.

KRAS Mutation Effective Biomarker For Vectibix Success, Amgen Reports

Biotech adds to industry KRAS buzz with biomarker analysis from its “408” study of the anti-EGFR comparing effectiveness against wild-type and mutated tumors.

Table

View full table

Related Content

Pink Sheet
Pink Sheet

Topics

Tags:
BioPharmaceutical Europe
Latest Headlines

FDA Panel Will Have To Weigh Pediatric Cancer Drug’s ‘Higher Level’ Of Uncertainty Against Rare, Devastating Disease

Novo Files Suit Over IRA As It Joins Others In Signing On To Price Negotiations

IRA Litigation Hurdles Clarified With Ruling In Chamber Of Commerce Suit

Japan Approves Leqembi, All Eyes Now On Extended Pricing Discussions

See All
UsernamePublicRestriction

Register

PS066637

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By